biotech / news / / MarketScreener
Moderna surpassed Wall Street estimates for first-quarter revenue.
Moderna's international COVID-19 vaccine revenue was $311 million, significantly surpassing U.S. revenue of $78 million.
KEY POINTS
- U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. have reduced domestic vaccine use.
- Moderna's FDA application for its mRNA-based flu vaccine has progressed after resolving a trial design dispute.
- Late-stage data for Moderna's norovirus and individualized cancer vaccines are expected soon.
- Moderna paid $2.22 per share in charges to settle a patent dispute over lipid nanoparticle technology.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →